Ziv-aflibercept in macular disease

PurposeIn vitro and in vivo studies did not detect toxicity to the retinal pigment epithelium cells using intravitreal ziv-aflibercept. Our purpose is to ascertain the 3-month safety and efficacy in...

New Examination Methods for Macular Disorders: Application of Diagnosis and Treatment

Macular oedema is a common complication and vision-limiting factor in uveitis. The aim of this study was to compare retinal thickness as measured by optical coherence tomography and photoreceptor function as measured by fundus-related microperimetry with respect to their correlation with visual acuity. Prospective observational monocentre study. Thirty-one patients (53 eyes) with endogenous uveitis and fluorescein angiographically confirmed macular oedema were evaluated. Foveal thickness was analysed using spectral-domain (Spectralis(TM) ; Heidelberg Engineering, Heidelberg, Germany) OCT and retinal sensitivity was assessed using fundus-related microperimetry (MP1; Nidek Technologies, Padova, Italy). All findings were correlated with best-corrected visual acuity (BCVA). Foveal thickness was correlated with BCVA [p = 0.005, r = 0.38, 95% confidence interval (CI) 0.12-0.59]. For microperimetry measurements, a negative correlation with logMAR visual acuity was found. Fixation abnormalities were not associated with poor visual acuity, increased foveal thickness or retinal sensitivity. In eyes with cystoid changes in the outer plexiform and inner nuclear layer, foveal thickness was increased (p < 0.0001). Epiretinal membrane formation was present in 70%. In these eyes, foveal thickness was significantly increased (p = 0.003) and visual acuity was worse (p = 0.08). Foveal thickness and fundus-related microperimetry were correlated with visual acuity. Cystoid changes in the outer plexiform and inner nuclear layer and the presence of epiretinal membrane were associated with poor visual acuity. Fixation abnormalities were not associated with poor visual acuity.

The use of intravitreal corticosteroids in the management of macular oedema has recently gained widespread acceptance. New long-acting steroid preparations and methods of delivery have facilitated the use of these new modalities. This review describes the various types of macular oedema for which this therapeutic option is used and the results.

The impact of delayed anti-vascular endothelial growth factor treatment for retinal diseases during the COVID-19 lockdown

We propose a framework for automated detection of dry age-related macular degeneration (AMD) and diabetic macular edema (DME) from retina optical coherence tomography (OCT) images, based on sparse coding and dictionary learning. The study aims to improve the classification performance of state-of-the-art methods. First, our method presents a general approach to automatically align and crop retina regions; then it obtains global representations of images by using sparse coding and a spatial pyramid; finally, a multiclass linear support vector machine classifier is employed for classification. We apply two datasets for validating our algorithm: Duke spectral domain OCT (SD-OCT) dataset, consisting of volumetric scans acquired from 45 subjects—15 normal subjects, 15 AMD patients, and 15 DME patients; and clinical SD-OCT dataset, consisting of 678 OCT retina scans acquired from clinics in Beijing—168, 297, and 213 OCT images for AMD, DME, and normal retinas, respectively. For the former dataset, our classifier correctly identifies 100%, 100%, and 93.33% of the volumes with DME, AMD, and normal subjects, respectively, and thus performs much better than the conventional method; for the latter dataset, our classifier leads to a correct classification rate of 99.67%, 99.67%, and 100.00% for DME, AMD, and normal images, respectively.

To study the prevalence and age- and gender-related gradient of ophthalmic diseases (cataract, glaucoma, age-related macular degeneration, diabetic and hypertensive retinopathy) in the Russian population older than 50 years. A random population cohort (9360, aged 45-69 years) was examined in Novosibirsk in 2003/05 and re-examined in 2015/17 (the HAPIEE project). Ophthalmological parameters were studied in a random subsample (324 m/f, aged 55-84, 2015/17). Clinical and instrumental methods were applied to assess eye diseases: cataract, glaucoma, age-related macular degeneration (AMD), diabetic retinopathy (DR), hypertensive retinopathy (HR) and other ophthalmic diseases. In the studied sample of men and women aged 55-84 years, the prevalence of cataract was 72.8%, AMD - 25.7%, glaucoma - 6.2%, DR - 2.1%, HR - 79.6%. The prevalence of other ophthalmic diseases (myopia, hyperopia, astigmatism, pterygium, pinguecula, dystrophy of cornea and retina, tumors and inflammatory diseases) was 13.5%. The frequency of cataract (p<0.001) and AMD (p=0.003) significantly increased with age. The frequency of glaucoma did not change substantially in the studied age range with insignificant increase in those older than 80 years (14.3%). The frequency of DR and HR were not consistently related to age. In the studied population sample of men and women aged 55-84 years (Novosibirsk), the prevalence of cataract and HR is high; the prevalence of AMD is similar to populations with moderate frequency of diseases; the frequency of glaucoma is close to populations with high prevalence of this disease. The frequency of cataract and AMD increased with age. There was no consistent age gradient of the frequency of glaucoma, DR and HR in the age range of 55-84 years.

Prevalence and Significance of Subretinal Drusenoid Deposits (Reticular Pseudodrusen) in Age-Related Macular Degeneration

Ranibizumab for Retinal Neovascularization

To report short-term regression of neovascularization after varying intravitreal doses of bevacizumab (Avastin®; Genentech, San Francisco, California, USA) in patients with proliferative diabetic retinopathy (PDR). Eighty eyes from 76 patients with active neovascularization of the disc (NVD) or elsewhere (NVE) caused by PDR were divided into four groups and treated with a single intravitreal bevacizumab (IVB) injection of 1.25 mg, 600 μg, 300 μg or 150 μg, respectively. All patients underwent ophthalmoscopic examination and fluorescein angiography at baseline, 1 week, 1 month and 2 months later. No significant ocular or systemic adverse events were observed. In all patients with NVD or NVE, complete resolution of leakage was recorded within the first week or the first month of the injection. Even with the lowest dose (150 μg), regression of neovascularization appeared as early as the first week and lasted for over a month. Recurrence of fluorescein leakage was observed in all groups after the first month and did not correlate with the extent of neovascularization or IVB dose. Short-term results suggest that IVB given below the standard dosage (150–300 μg compared to 1.25 mg) can lead to the achievement of complete regression of diabetic retinal neovascularization within 30–45 days of injection.

Retinal vessel responses to flickering light are different in various systemic and ocular diseases and can be improved after successful therapy. We investigated retinal vessel response to flickering light in age-related macular degeneration (AMD) patients before and after treatment with a single intravitreal bevacizumab (Avastin(®) ) injection. In 10 patients with exudative AMD [age: median (1.quartile; 3.quartile) 76.0 (73.5; 80.0) years], retinal vessel reactions were examined by Dynamic Vessel Analyser (DVA) before and 3 months after a single intravitreal application of bevacizumab (1.25 mg). A baseline measurement was followed by three consecutive monochromatic flicker stimulations (530-600 nm, 12.5 Hz, 20 seconds). Temporal retinal vessel reaction was analysed and compared with the reaction in healthy controls. Mean arterial dilation at the end of flicker was not different in all groups. For veins this parameter amounted to: pre-treatment, 2.6 (1.7; 3.9)%; post-treatment, 2.9 (2.4; 4.0)%; control, 4.3 (3.2; 5.7)%; significant: pre-treatment - control (Dunnett's procedure, p < 0.05). Maximal dilation occurred in arteries at: pre-treatment, 17.5 (14.8; 32.5) seconds; post-treatment, 18.0 (16.6; 30.6) seconds; control, 14.5 (10.8; 17.3) seconds. Both AMD groups were slower (p < 0.05): in veins at 17.0 (14.5; 20.0) seconds, 12.8 (8.6; 14.8) seconds and 18.5 (17.1; 19.9) seconds, respectively; significant post-treatment - control (p < 0.05). In the post-treatment AMD group arterial constriction after stimulation occurred more slowly compared with the control group (p < 0.05). Dynamic retinal arterial and venous reactions to flickering light are altered in AMD compared with controls. Three months after a single injection of a vascular endothelial growth factor inhibitor, the investigated retinal dynamic vascular parameters were not altered in our study.

In diabetic macular edema (DME), identification of baseline markers on spectral-domain optical coherence tomography (SD-OCT) and their association with severity of diabetic retinopathy (DR) might aid in disease management and the design of future trials. To examine associations between DR severity, retinal morphology on SD-OCT, and visual acuity in participants with DME. This cross-sectional observational case series was conducted at a single tertiary care referral center. Demographics, visual acuity, SD-OCT, and color fundus photographs of 80 individuals with DME (102 eyes) seen between December 28, 2013, and April 30, 2014, were analyzed between May 1 and July 31, 2016. Features captured on SD-OCT and thickness metrics. On SD-OCT we graded type and shape of DME, shape and presence of septae within the intraretinal cystoid abnormalities, presence of hyperreflective dots and foci, integrity of the external limiting membrane and ellipsoid zone, presence and extent of disorganization of the inner retinal layers (DRIL), and the status of the vitreomacular interface and epiretinal membrane. We measured retinal thickness at the fovea and at the site of maximum pathology, choroidal thickness at the fovea, and 1000 μm temporal and nasal to the fovea. Color photographs were graded to derive a DR severity stage. The mean (SD) age was 63 (11) years, and 30 participants (37.5%) were women. The odds of having DRIL were greater in eyes with disrupted external limiting membrane (odds ratio [OR], 4.4; 95% CI, 1.6-12.0; P = .003), disrupted ellipsoid zone (OR, 2.7; 95% CI, 1.0-7.2; P = .03), presence of epiretinal membrane (OR, 2.8; 95% CI, 1.0-7.4; P = .03), and increase in retinal thickness at the fovea (OR, 1.6; 95% CI, 1.1-2.2; P < .001). Occurrence of DRIL was more likely in eyes with proliferative DR (OR, 7.3; 95% CI, 1.7-31.4; P = .007). Mean visual acuity decreased by approximately 4.7 letters for each 100-μm increase in the average global DRIL (95% CI, -7.9 to 1.4; P = .006). An association was found between DRIL and disruption of the outer retina and increasing DR severity. Further longitudinal studies seem warranted to determine whether DRIL is a clinically relevant noninvasive morphological marker in eyes with DME.

Purpose: To see the effect of Ranibizumab at 1-monthly and 2-monthly intervals on visual acuity and central macula thickness among patients with diabetic macular edema, neovascular age-related macular degeneration and diabetic retinopathy. Study Design: Retrospective review of clinical record. Place and Duration of Study: The present study was conducted at four eye centers (Al-Shami Eye Center, Sudan Eye Center, Makkah Eye Complex and Nor-Aloyon Eye Hospital) located at Khartoum state of Sudan from January 2021 and June 2021. Methods: A total of 109 records of patients with diabetic retinopathy, age related macular degeneration and macular edema were included. They were categorized into 4 groups; group A (wet age-related macular edema (WAMD, n = 16)), group B (macular edema (ME, n = 32)), group C (proliferative diabetic retinopathy (PDR, n = 31)), and group D (non-proliferative diabetic retinopathy and macular edema (NPDR + ME, n = 30)). All participants underwent full ophthalmic examination before the injection, at one month and two months after the injection. Means, standard deviations and frequencies were calculated. ANOVA was used to find any significant difference between the study groups and the impact of treatment. Results: Mean age of patients was 57.73 ± 10.44 years. There was significant improvement in terms of mean visual acuity from baseline to third follow up in all study groups, (F (1, 105) = 14.94, P &lt; 0.001), with no significant differences in this improvement between the study groups, F (1.83, 5.48) =14.6, P = 0.19. Conclusion: Use of Lucentis has demonstrated a statistically significant reduction in CMT and improvement in BCVA. However, none of the patients showed a complete resolution of edema at the end of last follow up.

Reply

This study was conducted to explore the prevalence and the associated factors of visual impairment and blindness among the elderly Taiwanese population. A nationwide population-based visual health care screening program of elderly people aged 65 years or older was conducted between 1 July 2002 and 31 December 2002 in Taiwan. Based on the same standardized protocol used by the Bureau of Health Promotion, Department of Health, and a stratified random sampling design, 3160 out of 5000 elderly subjects were selected by a two-stage visual care screening method. The overall response rate was 63.2%. The mean age of the elderly participants was 72.4 +/- 5.1 years. The overall prevalence of glaucoma, corneal diseases, trauma, cataracts, myopic or diabetic retinopathy, and age-related macular degeneration among the elderly population was 2.1%, 6.3%, 0.9%, 60.2%, 7.5%, and 2.9%, respectively. The overall prevalence of visual disability (visual acuity of the better eye <0.5) was 17.7%, including 17.1% with visual impairment and 0.6% with blindness. Based on logistic regression, the significant independent factors of visual disability (visual impairment plus blindness) were sex (male vs. female, odds ratio (OR) = 0.62, 95% confidence interval (CI), 0.51-0.76), age (70-74 years vs. 65-69 years, OR = 1.60, 95% CI, 1.24-2.06; 75-79 years vs. 65-69 years, OR = 2.52, 95% CI, 1.92-3.32, > or =80 yrs vs. 65-69 yrs, OR = 4.86, 95% CI, 3.52-6.70), corneal diseases (OR = 2.26, 95% CI, 1.61-3.16), myopic or diabetic retinopathy (OR = 1.69, 95% CI, 1.20-2.39), age-related macular degeneration (OR = 4.96, 95% CI, 3.16-7.78), and cataract (OR = 3.40, 95% CI, 2.67-4.33). The geographic difference in the prevalence of vision-related eye disease, visual impairment, and blindness point to the importance of taking actions that suit local circumstances. Our results also revealed that visual impairment and blindness are important visual health problems in the elderly Taiwanese population. Age-related macular degeneration, cataracts, corneal diseases, myopic or diabetic retinopathy, female sex, and aging were the leading causes of visual disability. Further organized preventive strategies for eye care are recommended in this population.